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A panel of five neutralizing monoclonal antibodies was generated from mice immunized with an attenuated strain of
Mengo virus. Four of the antibodies were used to select mutants of Mengo virus which were able to escape neutralization
by the selecting antibody, but it was not possible to select mutants which could escape neutralization by the fifth antibody.
The capsid coding region of the RNA genome of each mutant was directly sequenced to identify the mutation(s) responsible
for the neutralization escape phenotype. These results are compared to those of a previous study in which immunogenic
determinants recognized by neutralizing antibodies generated against pentameric capsid subunits were located on the
external surface of the Mengo virion. We have confirmed the existence of the previously identified immunogenic determinant
in VP3 (site 2) as well as an immunodominant determinant in VP2 (site 1). Two previously uncharacterized determinants,
located in surface loops of VP1 (sites 3 and 4), were also identified. None of the mutations conferring the neutralization
escape phenotype was found near the surface depressions on the virion which are believed to be the receptor binding
sites. q 1995 Academic Press, Inc.
INTRODUCTION tify some of the capsid surface elements which constitute
neutralization epitopes (Boege et al., 1991). Because of
Mengo virus is a member of the Cardiovirus genus of
the extreme pathogenicity of wild-type Mengo virus, im-
the Picornaviridae and a natural pathogen of mice. The
munization of mice using intact infectious virions for the
virion consists of 60 copies of each of four structural
generation of monoclonal antibodies is not possible.proteins surrounding a single-stranded RNA genome of
However, Duke and Palmenberg (1989) generated athe positive sense. Residues from three of the capsid
cDNA clone of Mengo virus that contained a truncatedproteins, VP1, VP2, and VP3, are exposed on the external
poly(C) tract in the 5* noncoding region of the RNA ge-surface of the virion, while the fourth (VP4) is located on
nome, and Duke et al. (1990) showed that this clonethe inner surface of the capsid shell. The structure of the
produced viruses which were attenuated for mice. ThisMengo capsid has been determined to 3-A˚ resolution
Mengo strain has recently been used as a vector for live(Luo et al., 1987; Krishnaswamy and Rossmann, 1990).
recombinant vaccines (Altmeyer et al., 1994, 1995), andIntraperitoneal injection of Mengo virus in mice results
we have used it as an immunogen to further the charac-in severe damage to many different cells and tissues,
terization of Mengo virus B-cell epitopes recognized byincluding neurons of the central nervous system and car-
the mouse.diac muscle (Stringfellow et al., 1974). Hindlimb paralysis
B-cell epitopes of a large number of picornavirusesis the first observable symptom, and the infected mice
have been mapped using monoclonal antibodies gener-usually die from severe meningoencephalitis (Vecken-
ated from immunized mice. These include poliovirus (ge-stedt, 1974; Guthke et al., 1987). Although rodents are
nus Enterovirus: relevant recent publications are Hoglebelieved to be the natural reservoir of Mengo virus, it
and Filman, 1989; Weigers et al., 1990; Roivainen et al.,has been associated with serious infections of a variety
1991; Reynolds et al., 1991; Patel et al., 1993), Coxsackieof animals, including pigs (Dea et al., 1991) and primates
B virus (genus Enterovirus: Haarmann et al., 1994), bovine(Hubbard et al., 1992).
enterovirus (genus Enterovirus: Smyth et al., 1990), hu-Monoclonal antibodies generated in mice against the
man rhinoviruses 2 and 14 (genus Rhinovirus: Rossmann13.4S pentameric subunits derived from dissociated
et al., 1985; Sherry et al., 1986; Speller et al., 1993), footMengo virions (Mak et al., 1974) have been used to iden-
and mouth disease virus (genus Aphthovirus: Saiz et al.,
1991; Crowther et al., 1993), human hepatitis A virus (ge-
1 Present address: Department of Virology and Molecular Biology, nus Hepatovirus: Ping and Lemon, 1992), and Theiler’sSt. Jude Children’s Research Hospital, Memphis, TN 38101.
murine encephalitis virus (genus Cardiovirus: Kim et al.,2 To whom correspondence and reprint requests should be ad-
dressed. 1992; Roos and Casteel, 1992). However, with the excep-
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tion of the Theiler’s virus, these viruses do not produc- 1.5 hr with a 1:1500 dilution (100 ml/well) of alkaline phos-
phatase-conjugated goat anti-mouse IgA-, IgG-, and IgM-tively infect mice and the murine B-cell response to these
viruses may not be entirely representative of the protec- specific antibody mixture (Cedarlane Laboratories, Horn-
by, Ontario). Bound alkaline phosphatase-conjugated an-tive response which occurs in their natural hosts.
We have examined the B-cell response generated in tibody was detected by the addition of 100 ml/well of
substrate [5 mg p-nitrophenyl phosphate (Sigma 104-105)mice to infectious, attenuated Mengo virus and identified
a number of monoclonal antibodies which specifically in 5 ml 10% diethanolamine, pH 9.8]. Positive results were
quantitated at 410 nm with an ELISA plate reader (MR600recognize and neutralize the virus. The epitopes recog-
nized by most of these monoclonal antibodies were iden- Micro Plate Reader, Dynatech Laboratories Inc.).
tified by sequencing of naturally occurring neutralization
Determination of monoclonal antibody isotypeescape mutants and compared with those identified in
our earlier study (Boege et al., 1991), which used nonin- ELISA plates were coated with Mengo virus as in the
fectious subviral pentamers as immunogen. ELISA procedure. The antibody type in undiluted hybridoma
tissue culture supernatant or ascites fluid diluted in PBS
METHODS was determined with the Bio-Rad Mouse Typer Isotyping
kit (172-2051) according to the instructions provided.Production and purification of Mengo virus
Microneutralization and cross-neutralization assaysConfluent mouse L-929 cell monolayers in roller bottle
cultures were infected with Mengo virus (M plaque vari- The resistance of each mutant virus isolate to each of
ant; Ellem and Colter, 1961) at low multiplicity of infection the neutralizing monoclonal antibodies was tested in a
(0.1 plaque-forming unit, PFU, per cell). Purified Mengo microtiter neutralization test. In each well, 50 ml of undi-
virus was prepared from tissue culture supernatants as luted hybridoma supernatant was incubated with 50 ml
described previously (Ziola and Scraba, 1974; Boege et of mutant isolate at 100-fold 50% tissue culture infective
al., 1986). dose for 1 hr at 377, and then 5 1 104 L-929 cells, in 100
ml basal medium Eagle supplemented with 10% FCS,
Hybridoma production for anti-Mengo virus
was added. After 48 hr at 377, the plates were stained
monoclonal antibodies
with 0.1% crystal violet in 20% ethanol or examined by
light microscopy to detect cell lysis.BALB/c mice were initially injected, by the intraperito-
neal (ip) route, with 5 1 106 PFU of purified attenuated
Western blotsMengo virus (Duke et al., 1990; generously provided by
Dr. A. C. Palmenberg). Mice were given three ip booster Mengo virus capsid proteins (50 mg/lane) were sepa-
injections of 7.5 mg of purified wild-type Mengo virus at rated by electrophoresis in a 1-mm, 7.5% SDS– polyacryl-
30-day intervals, and those with a serum ELISA titer amide gel. The proteins were transferred to nitrocellulose
against Mengo virus of greater than 1:1000 were sacri- (Bio-Rad 162-0115) by wet electrophoretic transfer [10
ficed 3 days after the final injection. Hybridomas were mM CAPS (3-(cyclohexylamino)-1-propanesulfonic acid),
formed by PEG (PEG 3350, Sigma P-2906)-mediated fu- 10% methanol, pH 11.0] for 15– 18 hr at 60 V and 47.
sion of splenocytes with SP2/0 cells combined at a ratio Transfer was checked by staining the blot with 0.1% Coo-
of 8:1, respectively, and distributed into 96-well tissue massie brilliant blue in 50% methanol and destaining with
culture plates. Hybridomas positive for the production of 50% methanol and 10% acetic acid. The blot was blocked
anti-Mengo virus-specific antibodies were identified by with 3% BSA in PBS for 2 hr at 207 and then washed with
ELISA and cloned by limiting dilution. All monoclonal cell four changes of 150 mM NaCl, 50 mM Tris (pH 7.5). The
lines selected after one cycle of cloning were recloned bound alkaline phosphatase-conjugated antibodies were
to ensure that they were monoclonal. detected using bromochloroindolyl phosphate/nitroblue
tetrazolium (BCIP/NBT). The substrate solution used was
Enzyme-linked immunoadsorbant assays (ELISA) 66 ml NBT stock (5% NBT in 70% dimethylformamide) plus
33 ml BCIP stock (5% BCIP in 100% dimethylformamide)High protein affinity polystyrene ELISA plate (Immulon
in 10 ml alkaline phosphatase buffer (100 mM NaCl, 52, ‘‘U’’ plates, Dynatech Laboratories Inc.; supplied by
mM MgCl2 , 100 mM Tris, pH 9.5). The blot was developedFisher) wells were coated with purified Mengo virus (3
until the appearance of bands and the reaction wasmg/ml, 100 ml/well) overnight at 47 in ELISA-coating buffer
stopped by replacing the substrate with PBS containing(13.5 mM Na2CO3 , 34.9 mM NaHCO3 , pH 9.6). Each well
20 mM EDTA.was treated with 200 ml of 1% BSA (Sigma, fraction V, A-
4503) in PBS for 1 hour at 207. One hundred microliters
Selection of mutant Mengo virions which escapeof either undiluted hybridoma supernatant or ascites fluid
neutralizationdiluted in PBS– Tween was added to each well and the
plates were incubated for 2 hr at 207. To detect antibody The procedure used for the selection of mutants with
antibodies 370, 9B, and 352 has been described (Boegebound to the virion antigen, plates were incubated for
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et al., 1991). Mutants which escape neutralization by anti- synthesized using 1 mg of RNA with primer P27 (5*-TAG-
CAGGATGTGCAGAGT-3* ) and 200 units of Superscriptbody 3A could not be selected from the wild-type stock
of Mengo virus, but could be selected by the same proce- reverse transcriptase (GIBCO BRL). The cDNA was am-
plified by PCR with addition of primer P7 (5*-CAGTCA-dure using a stock of mutant virus 4/12 (selected for its
ability to escape neutralization by monoclonal antibody ACGACTCCTCAGGGT-3*) which binds outside the cap-
sid coding region of the genome. The 2640-bp fragmentMCP4; Boege et al., 1991), which has a lysine to threo-
nine mutation at position 2148 in VP2. It was not possible was excised from an agarose gel, purified with Gen-
eClean (Bio101), and ligated into the EcoRV-digestedto select mutants which escape neutralization by anti-
body 6A from either wild-type Mengo virus or stocks of pBluescriptII (SK/) (Stratagene) using standard tech-
niques (Sambrook et al., 1989).any of the mutants of Mengo virus selected to escape
neutralization by other monoclonal antibodies (MAbs).
DNA sequencingThe actual frequencies of mutation were not determined
for each mutant, but all were in the range (1003 to 1005) Plasmids containing inserts were purified using Qia-
which had been calculated for mutations escaping neu- gen columns (Qiagen Inc.) and then sequenced using a
tralization by anti-pentamer MAbs (Boege et al., 1991; PRISM Dyedeoxy Terminator Cycle Sequencing kit (Ap-
Table 1). plied Biosystems) with primers covering the capsid re-
gion. Reactions were processed with an Applied Biosys-RNA extraction from mutant viruses
tems 373A automated DNA sequencer and analyzed us-
Pellets of mutant virus obtained from 6 1 108 infected ing the Applied Biosystems Seqed program.
cells were resuspended in 2.25 ml RNA buffer (100 mM
KCl, 10 mM Tris, 1 mM EDTA, pH 7.2, containing 1% SDS) Ribbon diagrams
and extracted three times with equal volumes buffer-
The ribbon diagrams of Mengo capsid proteins VP1,saturated phenol:chloroform (4:1). After three washes of
VP2, and VP3 were generated from the crystallographicthe aqueous phase with buffer-saturated ether and re-
coordinates for the virus (Brookhaven Protein Data Bank)moval of residual ether by N2 , 200 ml of 2 M sodium using the graphics program MOLSCRIPT (Kraulis, 1991).acetate (pH 5.0) was added and the RNA precipitated
with three volumes of cold (0257) absolute ethanol. The Nomenclature
pellet was recovered by centrifugation, dried under vac-
Amino acid residues are identified by their position inuum, resuspended in 50 ml water, and stored at 0257.
the polypeptide sequence preceded by 1, 2, 3, or 4 de-
RNA sequence determination pending on respective capsid protein VP1 through VP4.
This procedure has been described previously (Boege
RESULTSet al., 1991).
Five monoclonal cell lines which produced neutralizing
cDNA synthesis and cloning antibody against Mengo virus were generated by fusions
of splenocytes from mice immunized with the attenuatedNeutralization escape mutants selected with antibody
Mengo virus with myeloma cells. The cell lines were3A do not replicate efficiently in culture so it was not
initially identified using ELISA to screen for the presencepossible to obtain sufficient mutant virus to isolate RNA.
of virus-specific secreted antibody and then screened inSequences of the mutants were determined from PCR-
microneutralization assays to identify which were capa-amplified cDNA produced from cytoplasmic RNA in in-
ble of neutralizing Mengo virus infectivity in vitro. Thefected cells. Cytoplasmic RNA was purified from Mengo
names and immunoglobulin class of the MAbs secretedvirus-infected mouse L-cells by the method of Sambrook
by these hybridoma cell lines are listed in Table 1.et al. (1989). cDNA from the capsid coding region was
Neutralization escape mutants were selected from
wild-type Mengo virus stock using MAbs 370 (mutants
TABLE 1 370/1-L, 2-L, 5, and 8-L), 9B (mutants 9B/2, 3, 4, and 9),
and 352 (mutants 352/1, 5, 6, and 7). It was not possibleAntibody Typing of Various Monoclonal
Antibody-Producing Cell Lines to select mutants from wild-type Mengo virus which were
capable of escaping neutralization by either MAb 6A or
Monoclonal Immunoglobulin 3A. However, it was observed during characterization
antibody class
of these two antibodies that mutants which did escape
neutralization by 3A could be selected from pools of mu-370 IgM
3A IgA tants which had previously been selected for their ability
6A IgG2A to escape certain anti-Mengo virus MAbs which had
9B IgM been generated from mice immunized with pentameric
352 IgM
subunits (see below). Neutralization escape mutants
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could be selected from pools of all mutants selected with 3A starting with mutant 6/16 or the mutants selected with
antibody MCP4 but not from wild type or any other mutantMCP4 or from mutant 6/16. Four mutants (3A/8, 9, 10,
and 11) were selected from mutant virus 4/12 stock with virus stock (Boege et al., 1991; see Fig. 1). This suggested
that MAb 3A binds to an epitope which includes the siteantibody 3A for further characterization. It was not possi-
ble to select neutralization escape mutants with MAb 6A of the mutations in these escape mutants. Together these
results indicate that the epitopes recognized by MAbsfrom either wild-type Mengo virus stock or stocks of any
of the other available mutants of Mengo selected with MCP4, 5, 6, and 3A overlap extensively, are distinct from
the epitopes recognized by the other MAbs, and togetherother anti-Mengo antibodies.
Initial characterization of the antibodies and mutants define one antigenic determinant, termed site 1, on the
Mengo virion (Table 3).was done with a series of cross-neutralization assays in
which the ability of each antibody to neutralize the mu- MCP1 was found to be capable of neutralizing mutants
selected with all of the other antibodies. This is in con-tants selected with all of the other antibodies was tested
(Fig. 1). These assays included the mutants and antibod- trast to the results we originally reported, which indicated
that MCP1 would not neutralize the mutants selectedies described in Boege et al. (1991). MAb 6A, for which
no neutralization mutants could be selected, completely with the other anti-pentamer antibodies MCP4, 5, and 6
(Boege et al., 1991). This error likely resulted from useneutralized the infectivity of wild-type virus and all the
mutants. of insufficient antibody in the cross-neutralization tests.
MAbs 352 and 370 neutralized all the mutants selectedMCP4 neutralized all mutants viruses except 5/01-S,
5/01-M, 5/01-L, 6/16, and the mutants selected with anti- with the other antibodies, and none of the mutants se-
lected with either MAb were neutralized by any otherbody 3A. MCP5 neutralized all mutants except those se-
lected with antibody 3A. MCP6 did not neutralize mutants antibody. None of the mutants selected with MAb 9B
escape neutralization by the other MAbs although 9B5/01-S, 5/01-M, and 5/01-L or the mutants selected with
antibodies MCP4 and 3A. Although MAb 3A neutralized could not neutralize mutants 1/01, 5/01-L, 5/11-L, and
352/1.all the mutants selected with other antibodies, it was
possible to select neutralization escape mutants to MAb The precise locations of the epitopes recognized by
the antibodies in the virus capsid were identified by com-
plete sequencing of the region of each mutant genome
coding for capsid proteins VP1, VP2, and VP3. For mu-
tants selected with antibodies 370, 9B, and 352, the RNA
genomes were sequenced directly using 12 different syn-
thetic oligonucleotide primers designed to cover the re-
gion of interest. It was necessary to use an alternative
approach to map the mutations in mutants selected with
antibody 3A because these mutants did not produce sig-
nificant amounts of virus when grown in culture, even
though they were able to infect cells. To determine the
position of neutralization escape mutations in the capsid
of these viruses, cDNA was produced from Mengo virus
RNA isolated from infected cells, amplified by the poly-
merase chain reaction, and sequenced in the capsid cod-
ing region with the primers used for RNA sequencing.
Table 2 indicates the location of the nucleotide muta-
tion(s) found for each mutant and the resulting amino
acid changes in the capsid proteins. The mutants se-
lected with MAb 370, designated 370/1-L, 2-L, 5, and 8-
L, all have a mutation at residue 1100 in VP1. The MAb
9B-selected mutants (9B/2, 3, 4, 9) all have a mutation
resulting in a change in either residue 1049 or 1062 in
VP1, and mutant 9B/4 has an additional mutation at resi-
due 2016 in VP2. The latter is a secondary mutation and
is not likely to be involved in the neutralization escape
phenotype of the mutant: residue 2016 is buried in the
interior portion of the capsid protein and mutants 9B/2
FIG. 1. Cross-neutralization pattern showing the anti-Mengo virus and 9B/9 also have mutations at residue 1062 which
monoclonal antibodies and the escape mutants. Mutants selected with alone are sufficient to confer neutralization resistance toone monoclonal antibody were tested for the ability to escape the
MAb 9B. The mutants selected with MAb 352 (352/1, 5,other monoclonal antibodies; h represents mutants which escaped
neutralization; j represents neutralization of the mutant. 6, 7) have mutations at residues 3073, 3074, and 3075 in
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TABLE 2
Changes in Nucleotide Sequence and Amino Acid Sequence of Mengo Virus Escape Mutants
Amino acid changeb
Mutant Nucleotide
virus changea VP1 VP2 VP3
370/1-L 2928 A r G 1100 Thr r Ala
370/2-L 2929 C r U 1100 Thr r Ile
370/5 2929 C r U 1100 Thr r Ile
370/8-L 2929 C r U 1100 Thr r Ile
9B/2 2814 A r G 1062 Asn r Asp
9B/3 2775 A r C 1049 Lys r Gln
9B/4 1217 A r C 2016 Gln r His
2814 A r C 1062 Asn r His
9B/9 2814 A r G 1062 Asn r Asp
352/1 2775 A r C 1049 Lys r Glnc
2154 A r C 3073 Lys r Gln
352/5 2160 C r G 3075 Gln r Glu
352/6 2158 C r U 3074 Thr r Ile
352/7 1600 A r G 2144 Asn r Serc
3A/8d 1599 A r G 2144 Asn r Asp
3A/9 1599 A r G 2144 Asn r Asp
2347 C r U 3137 Thr r Ile
3A/10 1599 A r G 2144 Asn r Asp
3A/11 1599 A r G 2144 Asn r Asp
a The nucleotide numbers refer to the position in the wild-type Mengo virus genome, beginning with nucleotide 1 at the 5*-end [the complete
poly(C) tract is included].
b The amino acid residues are identified according to the ‘‘Rossmann system,’’ with the first digit representing viral capsid protein 1, 2, or 3, and
the next three digits indicating position from the N-terminal.
c The mutation at residue 1049 in escape mutant 352/1 is probably a second site mutation. The mutation at 2144 indicates that antibody 352 may
span sites 1 and 2 (Table 3; see text).
d Escape mutants for antibody 3A were selected from a stock of virions which already contained a Lys r Thr mutation at residue 2148.
VP3 or at residue 2144 in VP2. Mutant 352/1 has an assays (Parry et al., 1989) using the same peptide panel
to compete for binding to virions were not successful.additional mutation at residue 1049 in VP1, which is prob-
ably a secondary mutation. However, this mutation, as Based on the patterns of cross-neutralization and the
sequencing data, four B-cell determinants on the Mengowell as secondary mutations in mutants 1/01, 5/01-L, and
5/11-L at residues 1049 or 1062, confers neutralization virion have been identified. The results are summarized
in Table 3. Our previous study (Boege et al., 1991) whichresistance to MAb 9B (Fig. 1).
All of the mutants selected with MAb 3A have a lysine mapped the B-cell determinants of the Mengo virion us-
ing monoclonal antibodies against pentameric subunitsto threonine mutation at residue 2148 of VP2 of the start-
ing mutant 4/12 virus stock. Mutant 3A/9 was completely of the virion identified two separate determinants, site 1
and site 2. Site 1, recognized by MAbs MCP4, 5, and 6,sequenced and two additional mutations were identified
in the capsid proteins at residue 3137 of VP3 and at 2144 includes residue 2075 in the bB –bC loop of VP2 (Luo et
al., 1987) and residues 2144, 2145, 2147, and 2148 in theof VP2. Sequencing in these regions of mutants 3A/8, 10,
and 11 showed that all had the same mutation at residue
2144 but none of the other mutants had a change at
residue 3137.
The epitope recognized by MAb 6A could not be identi-
fied by the selection and sequencing of neutralization
escape mutants. Alternative methods were attempted to
characterize the binding site of MAb 6A and the Mengo
virion. Western blot analyses of this antibody against the
individual capsid proteins of the virus indicate that it
specifically recognized VP2 (Fig. 2). Additional attempts
to characterize its binding site by direct binding of anti- FIG. 2. Western blot analysis of Mengo virus capsid proteins using
body to overlapping peptides (Bolwell et al., 1989) repre- monoclonal antibody 6A (lane 1). Lane 2 contains the major Mengo
virus capsid proteins stained with Coomassie brilliant blue.senting all of capsid protein VP2 and competition binding
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TABLE 3 receptor (Luo et al., 1987; Rossmann and Palmenberg,
1988) and, as expected, none of the antigenic determi-B-Cell Determinants on the Mengo Virion
nants involve residues located in or near the pit. Such
Recognized mutations would not be viable since they would destroy
Antigenic by the receptor binding ability of the virus.
(neutralization) monoclonal Escape Location in the
sitea antibodyb mutants virus capsidc
DISCUSSION
1 MCP4, MCP6 K2075 VP2: loop
between bB In a previous study two antigenic determinants of
and bC Mengo virus (sites 1 and 2; Table 3) were identified using
MAbs generated against pentameric subunits (Boege etMCP4, MCP5, N2144 VP2: surface
MCP6, 3A R2145 ‘‘puff’’ al., 1991). The analysis of antigenic determinants has
between bE been continued using five hybridoma cell lines, which
MCP4, MCP6 S2147 and aB secrete neutralizing MAbs, that were generated from
K2148
mice immunized with infectious attenuated Mengo virus.
2 MCP1 K3057 VP3: surface Four of the antibodies were used to select naturally oc-
MCP1 A3061 ‘‘knob’’ curring neutralization-resistant mutants but mutants
MCP1 S3068 inserted in
could not be selected which could escape the fifth anti-bB
body (MAb 6A). The capsid protein coding region of the
352d K3073 VP3: loop genome of each mutant was sequenced to identify the
T3074 between bB
mutation(s) responsible for the ability of the mutant toQ3075 and bC
escape its selecting antibody. The positions of these mu-
3 370 T1100 VP1: loop II tations were then mapped on the three-dimensional
between bC
structure of the virion (Luo et al., 1987; Krishnaswamyand aA
and Rossmann, 1990). The results are summarized in
4 9B K1049 VP1: carboxyl- Table 2 and Fig. 3.
end of bB
Antivirion MAb 3A was shown to recognize an epitope
9B N1062 VP1: loop containing residues within site 1. MAb 3A is of interest
between bB because a single mutation within its epitope did not confer
and bC
neutralization resistance. Neutralization escape mutants
could be selected from virions with a preexisting aminoa The anti-pentamer MAbs MCP4, MCP5, and MCP6 have been as-
signed to site 1 and MCP1 assigned to site 2 based on corrected data acid mutation (lys r thr at residue 2148) within site 1. All
from Boege et al. (1991). mutants so selected were found to contain an identical
b Antibodies MCP4, MCP5, and MCP6 eere raised using pentamers; additional mutation at residue 2144, suggesting that MAb
352, 9B, 3A, and 370 were raised using attenuated Mengo virus.
3A has a sufficiently high affinity for its epitope and that atc See Luo et al. (1987) and Fig. 3.
least two mutations within its virion binding site are re-d Cross-neutralization data (Fig. 1) do not indicate that the epitopes
recognized by antibody 352 and MCP1 are in the same site; however, quired to abrogate recognition. The mutations must also
the escape mutations from both are in close proximity on the surface occur at specific residues because not all mutants which
of the virion (Fig. 4). had a single mutation within site 1 could be used as a
starting stock from which to select neutralization escape
mutants. To our knowledge, this is the first example of abE–aB loop of VP2. Site 2, recognized by MCP1, includes
residues 3057 and 3061 in the surface ‘‘knob’’ inserted picornavirus neutralizing MAb that requires more than one
mutation in its viral epitope for escape from neutralization.in bB of VP3 as well as residue 3068 in the bB –bC loop
of VP3. In this study antibodies which bind to sites 1 and MAb 6A is another example of an antibody which is able
to neutralize Mengo virus very efficiently, since no escape2 as well as to two previously unidentified epitopes on
the virion have been characterized. MAb 3A recognizes mutants could be isolated for this antibody, even when
other neutralization escape mutants were used as startingsite 1, while MAb 352 may overlap sites 1 and 2 and
probably expands the residues recognized as part of site stocks. It was possible to show an interaction of MAb 6A
with VP2 polypeptides by Western blotting. MAb 6A may2 to include 3073 – 3075 in the bB –bC loop of VP3. Site
3, recognized by MAb 370, includes residue 1100 in loop also require multiple mutations within its binding site for
virions to escape neutralization. Functional studies haveII between the bC strand and aA helix of VP1. Site 4
contains residues 1049 and 1062 located in the bB –bC demonstrated that epitopes may contain far fewer amino
acid residues which are necessary for specific recognitionloop of VP1 and is recognized by MAb 9B (Fig. 3).
The relative positions of the four immunogenic deter- than the total number of residues which are in the contact
region of the antibody (Geysen et al., 1984; Getzoff et al.,minants of the Mengo virion and the ‘‘pit’’ are shown on
the schematic diagram in Fig. 4. The pit is believed to 1987; Jin et al., 1992). This would suggest why most neutral-
ization escape mutants selected with a given MAb gener-be the site of interaction of the virion with its cellular
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FIG. 3. Ribbon diagram of the biological protomer of Mengo virus showing the location of the four antigenic sites defined by ‘‘escape’’ mutants.
VP1 is blue, VP2 is green, and VP3 is red. The letter C designates the last residue visible in the original electron density map for VP1 (P1259);
amino-termini of VP2 and VP3 are indicated with the letter N. Ball-and-stick representations of the amino acid residues defining sites 1 (K2075,
N2144, R2145, S2147, and K2148), 2 (K3057, A3061, S3068, K3073, T3074, and Q3075), 3 (T1100), and 4 (K1049 and N1062) are shown in black. The
location of the ‘‘pit,’’ the putative receptor-binding site (Luo et al., 1987), is indicated by the sunburst symbols. The five- and threefold axes of the
virion are marked by the black symbols to show the orientation of the biological protomers in the capsid structure.
ally require only a single mutation, often occurring at the the infected host because it is highly unlikely that multiple
mutations will occur simultaneously in a given virion withinsame critical residue in all mutants, to escape recognition.
Both MAb 3A and (perhaps) MAb 6A are unusual in this the binding site of a single monoclonal antibody.
The epitope recognized by MAb 352 is enigmatic. Es-regard because a single mutation cannot confer neutraliza-
tion resistance. Such antibodies would be advantageous for cape mutants 352/1, 352/5, and 352/6 have single amino
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such changes would have a deleterious effect on capsid
stability and/or function.
Neutralization epitopes of Mengo virus were analyzed
by Muir et al. (1991) using a peptide-based system. They
tested the ability of antisera generated in mice against
each of 140 overlapping synthetic peptides, covering all
of the sequences of the four capsid proteins, to neutralize
Mengo virus. Only one of these peptides, corresponding
to residues 1259– 1277 of the external and flexible car-
boxyl-end of VP1, induced significant levels of polyclonal
FIG. 4. (A) Diagrammatic representation of the Mengo virus capsid. neutralizing antibodies. This epitope was not identifiedThe capsid is assembled from five pentamers, one located at each of
in our experiments using either subviral pentamers orthe 12 vertices of a regular icosahedron. The biological protomers (VP1,
live attenuated virus as immunogen. Muir et al. (1991)VP2, VP3) which comprise one pentamer (gray) are outlined with thick
black lines. (B) A single pentamer showing the locations of antigenic also reported that three other peptides in VP1 (residues
sites 1 –4. None of these are located in close proximity to the surface 1041– 1050, 1081 –1090, and 1163 – 1172) induced a very
depression (‘‘pit’’) which is thought to be the binding site for a cellular weak neutralizing response against Mengo virus. One ofreceptor.
these peptides contains residue 1049 that is part of the
epitope recognized by MAb 9B.
The three-dimensional structure of the Mengo capsidacid changes in the bB –bC loop of VP3 (the K1049Q
(Luo et al., 1987) revealed a number of linear amino acidmutation in 352/1 is likely not involved in neutralization
sequences predicted to be candidates for immunogenicby the antibody). We have tentatively assigned these mu-
epitopes. These sites include the two loops between bBtations to site 2 because of their proximity to those resi-
and aA regions in VP1 (residues 1078 to 1083 and 1093dues in the epitope recognized by MCP1 (Fig. 4), but this
to 1105) and the prominent bE –aA loop in VP2 (residuesassignment was not confirmed by the cross-neutraliza-
2154 to 2165). Of these sites, only the loop in VP1 con-tion experiments (Fig. 1). The N2144S mutation was the
tained a neutralizing immunogenic epitope (recognizedonly one found in mutant 352/7. It is conceivable that this
by MAb 370; Table 3). While it may be possible that wecould be a second site mutation, with the real escape
have not examined a sufficient number of antibodies tomutation remaining undetected. Alternatively, the epitope
identify these other sites, it is clear from the current
recognized by MAb 352 may in fact span sites 1 and 2.
results that neutralizing antibodies recognize regions of
The closest approach of these residues would be be- the capsid exposed on the surface but not necessarily
tween the VP3 residues of one pentamer and the VP2 on prominent protrusions. It is possible that more specific
residues from an adjacent protomer across the icosahe- residues within the antibody binding site are required for
dral twofold axis; this suggests that this epitope may stable binding than are critical for the initial recognition
comprise surface residues from two adjacent pentamers. of the epitope (Jin et al., 1992), and an extended loop may
The distance between these residues on the surface of not provide enough surface contacts for stable binding.
a single protomer would approach the 30-A˚ limit of the Second, it is not unreasonable to speculate that host
diameter of an antibody footprint (Davies et al., 1990). antibodies are produced against all parts of the surface
In addition to confirming the existence of sites 1 and of the virus, including the highly accessible loops, but
2, originally identified with the anti-pentamer MAbs, two binding to these loops may not provide the required anti-
additional neutralization determinants have been identified body– antigen interaction for neutralization of virus in-
with the anti-virion MAbs. Site 3 is defined by the epitope fectivity. In this context, peptide vaccines designed solely
recognized by MAb 370 and site 4 is defined by the epitope on the surface accessibility of linear determinants may
recognized by MAb 9B (Table 3). As in sites 1 and 2, the be ineffective; additional factors must be considered in
mutations in neutralization-resistant mutants selected with determining whether a particular amino acid sequence
these MAbs are located on the surface of the capsid pro- can elicit a pathogen-neutralizing antibody response.
teins, again suggesting that mutant Mengo viruses avoid In a recent review Lea and Stuart (1995) used com-
the neutralizing activity of the antibody by directly altering puter graphics techniques to analyze the external sur-
the binding site of the antibody. Some mutations in foot- faces of picornavirus (HRV-14, FMDV-O1 , poliovirus-1,
and-mouth disease virus and poliovirus at sites not directly and Mengo virus) capsids with respect to exposed amino
accessible to antibody binding can confer neutralization acid residues. Comparison with a control group of pro-
resistance by the disruption of hydrogen bonds or salt brid- teins revealed that the surfaces of picornavirus capsids
ges which cause a local disturbance in the conformation were particularly rich in threonine residues (21% of the
of an antigenic loop (Page et al., 1988; Parry et al., 1990; surface area as compared to 4% for control proteins).
Krebs et al., 1993). Mutations causing conformational dis- This observation led Lea and Stuart to suggest that threo-
ruption of an epitope at a site distant from the epitope have nine residues would be evolutionarily favored for the sur-
faces of proteins which depend on antigenic polymor-not been observed in picornaviruses, presumably because
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Mengo virus through genetic engineering of the 5* noncoding poly(C)phism for their survival. The rationale presented for this
tract. Nature 343, 474–476.hypothesis is that a transition mutation in either of the
Duke, G. M., and Palmenberg, A. C. (1989). Cloning and synthesis offirst two positions of the threonine codons (AC-) would infectious cardiovirus RNAs containing short, discrete poly(C) tracts.
yield alanine, isoleucine, or methionine. This change J. Virol. 63, 1822–1826.
could result in the replacement a polar serine residue Ellem, K. A. O., and Colter, J. S. (1961). The isolation of three variants
of Mengo virus differing in plaque morphology and hemagglutinatingwhich contributed specific recognition to an epitope (by
characteristics. Virology 15, 340– 347.hydrogen bonding with the antibody combining site) to
Getzoff, E. D., Geysen, H. M., Stuart, J. R., Alexander, H., Tainer, J. A.,a residue ‘‘not provoking strong interactions with immu-
and Lerner, R. A. (1987). Mechanisms of antibody binding to a protein.
noglobulins.’’ This they suggested, would ‘‘render the vi- Science 235, 1191– 1196.
rus less visible to the host immune system.’’ Inspection of Geysen, H. M., Meloen, R. H., and Barteling, S. J. (1984). Use of peptide
synthesis to probe viral antigens for epitopes to a resolution of athe Mengo capsid surface (Rossmann and Palmenberg,
single amino acid. Proc. Natl. Acad. Sci. USA 81, 3998– 4002.1988) shows that 13% of the exposed residues are
Guthke, R., Veckenstedt, A., Guttner, J., Stracke, R., and Bergter, F.threonines (24 out of a total of 183 in each capsid pro-
(1987). Dynaminc model of pathogenesis of mengo virus infection intomer). Of the 14 separate mutations which we have mice. Acta Virol. 31, 307– 320.
found to result in escape from neutralization by a mono- Haarmann, C. M., Schwimmbeck, P. L., Mertens, T., Schultheiss,
clonal antibody, only 2 involve threonine residues. Both H.-P., and Strauer, B. E. (1994). Identification of serotype-specific
and nonserotype-specific B-cell epitopes of coxsackie B virus usingof these fulfill the Lea and Stuart criterion in that the
synthetic peptides. Virology 200, 381–389.escape mutants all have either isoleucine or alanine as
Hogle, J. M., and Filman, D. J. (1989). The antigenic structure of polio-replacements; no third-position mutations were found.
virus. Philos. Trans. R. Soc. London, Ser. B 323, 467– 478.
However, the majority of the neutralization mutations fol- Hubbard, G. B., Soike, K. F., Butler, T. M., Carey, K. D., Davis, H., Butcher,
low no recognizable pattern with respect to transitions W. I., and Gauntt, C. J. (1992). An encephalomyocarditis virus epizo-
otic in a baboon colony. Lab. Anim. Sci. 42, 233– 239.vs transversions, position of the mutation within the co-
Jin, L., Fendly, B. M., and Wells, J. A. (1992). High resolution analysisdon, or replacement of polar/charged with nonpolar/un-
of antibody– antigen interactions. J. Mol. Biol. 226, 851–865.charged residues.
Kim, B. S., Choe, Y.-K., Crane, M. A., and Colleen, R. J. (1992). Identifica-
tion and localization of a limited number of predominant conforma-
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